Company Overview and News

 
Coface SA : AM Best attribue à Coface North America Insurance Company, la note A (Excellent) assortie d'une perspective « stable »

1h globenewswire
AM Best attribue à Coface North America Insurance Company, la note A (Excellent) assortie d'une perspective « stable »
COFA

 
Coface SA : AM Best assigns A (Excellent) rating to Coface North America Insurance Company, with stable outlook

1h globenewswire
Rating agency AM Best has just assigned Coface North America Insurance Company the 'A' (Excellent) Insurer Financial Strength (IFS) rating, with stable outlook.
COFA

 
Coface SA : Déclaration des transactions sur actions propres (hors contrat de liquidité) réalisées entre le 8 octobre et le 12 octobre 2018

2018-10-15 globenewswire
COFACE SA : Déclaration des transactions sur actions propres (hors contrat de liquidité) réalisées entre le 8 octobre et le 12 octobre 2018
COFA

 
Coface SA : Disclosure of trading in own shares (excluding the liquidity agreement) made between October 8th and October 12th 2018

2018-10-15 globenewswire
COFACE SA: Disclosure of trading in own shares (excluding the liquidity agreement) made between October 8th and October 12th 2018
COFA

 
Coface SA : Déclaration des transactions sur actions propres (hors contrat de liquidité) réalisées entre le 1 octobre et le 5 octobre 2018

2018-10-08 globenewswire
COFACE SA : Déclaration des transactions sur actions propres (hors contrat de liquidité) réalisées entre le 1 octobre et le 5 octobre 2018
COFA

 
COFACE SA: Disclosure of trading in own shares (excluding the liquidity agreement) made between October 1st and October 5th 2018

2018-10-08 globenewswire
COFACE SA: Disclosure of trading in own shares (excluding the liquidity agreement) made between October 1st and October 5th 2018
COFA

 
Coface SA : Déclaration des transactions sur actions propres (hors contrat de liquidité) réalisées entre le 24 septembre et le 28 septembre 2018

2018-10-01 globenewswire
COFACE SA : Déclaration des transactions sur actions propres (hors contrat de liquidité) réalisées entre le 24 septembre et le 28 septembre 2018
COFA

 
Coface SA : COFACE SA: Disclosure of trading in own shares (excluding the liquidity agreement) made between September 24th and September 28th 2018

2018-10-01 globenewswire
COFACE SA: Disclosure of trading in own shares (excluding the liquidity agreement) made between September 24th and September 28th 2018
COFA

 
Coface SA : Disclosure of total number of voting rights and number of shares in the capital as at September 30th, 2018

2018-10-01 globenewswire
COFACE SA: Disclosure of total number of voting rights and number of shares in the capital as at September 30th, 2018
COFA

 
Coface SA : Déclaration du nombre total des droits de vote et du nombre d'actions composant le capital social au 30 septembre 2018

2018-10-01 globenewswire
COFACE SA : Déclaration du nombre total des droits de vote et du nombre d'actions composant le capital social au 30 septembre 2018
COFA

 
Coface SA : Disclosure of trading in own shares (excluding the liquidity agreement) made between September 17th and September 21st 2018

2018-09-24 globenewswire
COFACE SA: Disclosure of trading in own shares (excluding the liquidity agreement) made between September 17th and September 21st 2018
COFA

 
Coface SA : Déclaration des transactions sur actions propres (hors contrat de liquidité) réalisées entre le 17 septembre et le 21 septembre 2018

2018-09-24 globenewswire
COFACE SA : Déclaration des transactions sur actions propres (hors contrat de liquidité) réalisées entre le 17 septembre et le 21 septembre 2018
COFA

 
Coface SA : Disclosure of trading in own shares (excluding the liquidity agreement) made between September 10th and September 14th 2018

2018-09-17 globenewswire
COFACE SA: Disclosure of trading in own shares (excluding the liquidity agreement) made between September 10th and September 14th 2018
COFA

 
Coface SA : Déclaration des transactions sur actions propres (hors contrat de liquidité) réalisées entre le 10 septembre et le 14 septembre 2018

2018-09-17 globenewswire
COFACE SA : Déclaration des transactions sur actions propres (hors contrat de liquidité) réalisées entre le 10 septembre et le 14 septembre 2018
COFA

 
Coface SA : Disclosure of trading in own shares (excluding the liquidity agreement) made between September 3rd and September 11th 2018

2018-09-11 globenewswire
COFACE SA: Disclosure of trading in own shares (excluding the liquidity agreement) made between September 3rd and September 11th 2018
COFA

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...